Samlyn Capital’s Terns Pharmaceuticals TERN Stock Holding History

Samlyn Capital’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-472,472	Closed	-$24.9M	–	97
2026 Q1	$24.9M	Sell	472,472 -342,403	-42%	-$14.1M	0.43%	60
2025 Q4	$32.9M	Buy	+814,875	New	+$18.8M	0.52%	48

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Samlyn Capital's TERN Position: Q2 2026 in Review

Samlyn Capital sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 472,472 shares — an estimated $24.9M sold.

Samlyn Capital first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $32.9M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Samlyn Capital reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Samlyn Capital sold 472,472 Terns Pharmaceuticals shares in Q2 2026, an estimated $24.9M.
Samlyn Capital first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Samlyn Capital's Terns Pharmaceuticals position peaked at $32.9M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Samlyn Capital's 13F filing for Q2 2026, filed 14 Aug 2026.